Pre-eclampsia

Targeted therapies

Potential targets include vascular endothelial growth factor (delivered by adenovirus vector), relaxin analogues, sildenafil, and other inflammatory agents.[96]Conrad KP. G-protein-coupled receptors as potential drug candidates in preeclampsia: targeting the relaxin/insulin-like family peptide receptor 1 for treatment and prevention. Hum Reprod Update. 2016 Sep;22(5):647-64. https://academic.oup.com/humupd/article/22/5/647/2237960 http://www.ncbi.nlm.nih.gov/pubmed/27385360?tool=bestpractice.com [97]Paauw ND, Terstappen F, Ganzevoort W, et al. Sildenafil during pregnancy: a preclinical meta-analysis on fetal growth and maternal blood pressure. Hypertension. 2017 Nov;70(5):998-1006. http://www.ncbi.nlm.nih.gov/pubmed/28893896?tool=bestpractice.com [98]Sibley CP. Treating the dysfunctional placenta. J Endocrinol. 2017 Aug;234(2):R81-97. https://joe.bioscientifica.com/view/journals/joe/234/2/JOE-17-0185.xml http://www.ncbi.nlm.nih.gov/pubmed/28483805?tool=bestpractice.com However, because the exact role of these substances in the disease process is unknown at this time, these approaches are not without risk, and there are no targeted therapies currently available.